摘要
Sphingosine-1-phosphate受体(S1PR)调节器已进入临床实践作为免疫调节剂治疗多发性硬化症(MS)。药理学的调制S1PR表情淋巴细胞抑制这些细胞能力应对S1P梯度区域内淋巴结(LNs)(胸腺)促进他们退出到末梢循环。结果外周血淋巴细胞减少限制被认为是构成S1PR调节器的能力,以减少新炎性病变形成女士在缺乏全球免疫抑制。这些调节器调节选择性进入淋巴细胞数量和树突状细胞(dc)LNs和调节sphingosine-1-phosphate(S1P)细胞信号网络管理特定细胞的生成在LNs子集。S1PR调节器,中枢神经系统也有功能的影响在这个舱由于S1PRs表达的细胞组成的血脑屏障(BBB)和那些在薄壁组织,包括神经元、星形细胞,胶质细胞和小胶质细胞。缺乏S1P1受体(S1PR1)星形胶质细胞可以降低实验性自身免疫性脑脊髓炎疾病严重程度(运算单元)。甚至抑制细胞反应条件下自然配体,S1PR调节器可以继续诱发积极信号响应;这样的反应可能是有关促进中枢神经系统内神经保护和增强组织修复。
关键词: FTY720. GPCR. 免疫调节剂. sphingosine-1-phosphate受体. 淋巴球减少症. 多发性硬化症.
Current Drug Targets
Title:Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Volume: 17 Issue: 16
Author(s): Luke M. Healy, Jack P. Antel
Affiliation:
关键词: FTY720. GPCR. 免疫调节剂. sphingosine-1-phosphate受体. 淋巴球减少症. 多发性硬化症.
摘要: Sphingosine-1-phosphate receptor (S1PR) modulators have entered clinical practice as immune-modulators for the treatment of multiple sclerosis (MS). Pharmacologic modulation of S1PR expression on lymphocytes inhibits these cells capacity to respond to the S1P gradient within regional lymph nodes (LNs) (and thymus) that promotes their exit into peripheral circulation. The resultant peripheral blood restricted lymphopenia is considered to underlie the capacity of S1PR modulators to reduce new inflammatory lesion formation in MS in the absence of global immune suppression. These modulators also regulate entry of selective lymphocyte populations and dendritic cells (DCs) into LNs and modulate sphingosine-1-phosphate (S1P) cell signaling networks that govern the generation of specific cell subsets within LNs. S1PR modulators that access the CNS can also have functional effects within this compartment since S1PRs are expressed by cells comprising the blood brain barrier (BBB) and by those within the parenchyma, including neurons, astrocytes, oligodendrocytes and microglia. Absence of S1P1 receptor (S1PR1) on astrocytes reduces disease severity in experimental autoimmune encephalomyelitis (EAE). Even under conditions that inhibit cell responses to the natural ligand, S1PR modulators can continue to induce active signaling responses; such responses may be relevant for promoting neuroprotection and augmenting tissue repair within the CNS.
Export Options
About this article
Cite this article as:
Luke M. Healy, Jack P. Antel , Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems, Current Drug Targets 2016; 17 (16) . https://dx.doi.org/10.2174/1389450116666151001112710
DOI https://dx.doi.org/10.2174/1389450116666151001112710 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition QSAR Study on a Series of Aryl Carboxylic Acid Amide Derivatives as Potential Inhibitors of Dihydroorotate Dehydrogenase (DHODH)
Medicinal Chemistry Antiviral Role of Toll-Like Receptor-3 Agonists Against Seasonal and Avian Influenza Viruses
Current Pharmaceutical Design Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Mesenchymal Stem Cells and Cell Therapy for Bone Repair
Current Molecular Pharmacology Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Oral Immune Regulation: A New Mode of Therapy Against Chronic Viral Infections
Recent Patents on Anti-Infective Drug Discovery Strategies for Improving the Quantitative Bioanalytical Performance of LC-MS in Pharmacokinetic Studies
Current Drug Metabolism Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Vitamin D Analogs- Drug Design Based on Proteins Involved in Vitamin D Signal Transduction
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design The Role of Skin and Gut Microbiome and Epigenetic Modifications in Skin-Autoimmune Disorders
Current Molecular Medicine Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Alpha Calcitonin Gene-related Peptide, Neuropeptide Y, and Substance P as Biomarkers for Diagnosis and Disease Activity and Severity in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Stem Cell Based Therapy for Autoimmunity (Guest Editor: Frank Alderuccio)]
Current Stem Cell Research & Therapy Advancement in Beneficial Effects of AVE 0991: A Brief Review
Mini-Reviews in Medicinal Chemistry